Polyethylene glycol 3350 with electrolytes

GoLYTELY: bowel cleansing before colonoscopy or barium-enema X-ray in adults. GaviLyte-N: before colonoscopy in adults and children ≥6 months. MoviPrep: before adult colonoscopy. Pediatric approval of one product does not establish approval of the others. No chronic constipation, poisoning or other off-label irrigation algorithm is supplied.

Mix supplied jug with lukewarm water to 4 L; dissolve by vigorous shaking, no added flavors/ingredients. Begin early evening before colonoscopy; drink 8 oz (240 mL) every 10 minutes until contents consumed or effluent clear. If prescribed via nasogastric tube, 20–30 mL/min (1.2–1.8 L/hour), with aspiration observation. Label allows light breakfast ≥2 hours before start; best results avoid solids 3–4 hours before start. Follow procedure-team diet/fasting plan; clear liquids until 2 hours before colonoscopy. Pediatric efficacy unestablished.

Each dose:1 Pouch A +1 Pouch B into supplied mixing container; add water to 32-ounce fill line and dissolve. Drink 8 oz every 15 minutes, about 1 hour to complete each dose. Split dosing is label-preferred: dose 1 evening 10–12 hours before dose 2, followed by≥16 oz clear liquid before bed; dose 2 next morning start≥3½ hours before colonoscopy, followed by≥16 oz clear liquid. Complete all dose 2/additional liquids≥2 hours before procedure. Alternative evening-only: start dose 1≥3½ hours before bed, start dose 2≥1½ hours after dose 1 start; after dose 2 drink 32 oz clear liquid before bed. Both require two complete doses and additional prescribed clear liquids; not just 2 L total intake.

Water only for mixing; no starch thickeners or other laxatives. Avoid red/purple liquids, alcohol/milk/pulp during MoviPrep treatment; only clear liquids after starting until 2-hour preprocedure cutoff. MoviPrep label permits specified breakfast/light lunch/dinner finished≥1 hour before start; follow package and procedure-team diet. GoLYTELY: no oral medicines within 1 hour before or during administration; section 7.2 has contradictory wording, so use consistent 2.1/17/Medication Guide instruction. MoviPrep: no oral medicines within 1 hour before or after starting each dose. GaviLyte-N warns medicines within 1 hour of start may flush through; individualized vital-medication plan required. Severe distention/discomfort: slow or briefly pause and contact clinician if persistent.

Selected products: GI obstruction, bowel perforation, gastric retention, ileus, toxic colitis/toxic megacolon or ingredient hypersensitivity. Exclude suspected obstruction/perforation with appropriate assessment before use. Renal impairment is a caution/monitoring issue in these labels, not an invented universal absolute contraindication.

Selected GoLYTELY, GaviLyte-N and MoviPrep labels have no boxed warning. Their Medication Guides and warnings describe potentially life-threatening fluid/electrolyte and aspiration complications.

Nausea, bloating/fullness, cramps, vomiting and anal discomfort are common; MoviPrep also reports thirst, malaise and sleep disturbance. Serious reported events include allergy, aspiration, arrhythmia, seizures, renal injury, esophageal injury/bleeding and ischemic colitis. MoviPrep overdose can produce severe dehydration and sodium/potassium disturbance: professional assessment, monitoring and symptom-directed treatment. Other selected labels supply no dedicated overdose regimen; do not invent home fluid/electrolyte correction or consume extra powder.

GoLYTELY 2.1/17/Medication Guide consistently prohibit oral medicines within 1 hour before and during use despite section 7.2 contradictory text. MoviPrep 2.1/Medication Guide/IFU prohibit them within 1 hour before or after starting EACH dose. GaviLyte-N warns absorption may be incomplete around the 1-hour pre-start interval. No universal postprep redosing rule; review antiseizure, transplant, diabetes and other essential medicines before the procedure.

Review medicines that affect fluid balance, renal function, electrolytes, QT or seizure threshold, including diuretics, ACE inhibitors/ARBs, NSAIDs and tricyclic antidepressants. Additional stimulant laxatives can increase mucosal injury/ischemic colitis; avoid adding them to these label regimens without a separately reviewed clinician plan. No automatic medication-hold schedule supplied by these labels.

Use caution with renal impairment; hydrate appropriately and consider baseline/postprocedure electrolytes, creatinine/BUN. Heart-failure hydration and cardiac-risk ECG assessment require individualized care. These labels provide no numerical renal/hepatic reduced-volume formula or dialysis regimen. Do not assume a smaller unauthorized volume is equivalent.

Only selected GaviLyte-N supports children ≥6 months; 25 mL/kg/hour oral/NGT under supervision, with hypoglycemia monitoring below 2 years and awareness of pediatric dehydration/hypokalemia reports. GoLYTELY/MoviPrep pediatric safety/effectiveness unestablished. Older adults may be more susceptible to organ/electrolyte complications even when trials show no overall age difference; assess risk rather than invent a reduced dose.

GoLYTELY/GaviLyte-N pregnancy evidence is limited, use only clearly needed; human milk excretion unknown, caution. MoviPrep has no adequate human pregnancy or milk/infant data: consider maternal clinical need, infant risk and breastfeeding benefit. No blanket pregnancy-safe declaration or automatic milk-discard interval.

PEG 3350 retains water in the colon, producing watery stool and bowel clearance; MoviPrep’s mixture including ascorbate contributes osmotic action. GoLYTELY/GaviLyte-N labeling describes rapid cleansing usually within 4 hours, not a guaranteed completion time for every patient.

GoLYTELY/GaviLyte-N product-specific PEG PK was not assessed; general oral PEG data suggest poor absorption. Selected MoviPrep label supplies no numerical product bioavailability/half-life or serum target. Safety decisions rest on hydration, renal/cardiac risk and preparation tolerance, not an invented serum PEG level.

Review hydration/electrolytes, renal/cardiac conditions, seizure history, swallowing, GI obstruction risk and all medicines. Correct abnormalities; consider risk-based labs and ECG before/after procedure. Monitor fluid intake, vomiting, urination, consciousness and abdominal symptoms; assess young GaviLyte-N patients for hypoglycemia. MoviPrep: assess PKU/G 6 PD and ingredient allergy. No universal fixed lab timetable.

Read exact Medication Guide/IFU, use supplied fill line, never swallow dry powder and drink required additional clear liquids. Confirm fasting cutoff with procedure team and do not share preparation. Severe vomiting, oliguria, dizziness/faintness, seizure/confusion, severe pain/rectal bleeding or allergic symptoms need urgent assessment; persistent severe discomfort warrants clinician contact. Do not compensate for a missed/incomplete preparation by an unreviewed extra jug or another laxative.

Selected package

Azurity 4 L jug, NDC 24338-236-01; white powder, prescription.

Per full jug

PEG 3350 236 g; sodium sulfate 22.74 g; sodium bicarbonate 6.74 g; sodium chloride 5.86 g; potassium chloride 2.97 g.

After 4 L dilution

PEG 59 g/L; sulfate 5.69 g/L; bicarbonate 1.69 g/L; NaCl 1.47 g/L; KCl 0.743 g/L (rounded label values).

GaviLyte-N

Sulfate-free 4 L jug: PEG 420 g, bicarbonate 5.72 g, NaCl 11.2 g. KCl is internally inconsistent 1.4 g in 2.1/11 versus 1.48 g in 3/16; no compounding instruction or presumed correction. Verify current pharmacy/package. NDC 43386-050-19.

MoviPrep

Two A/B pairs. Each A: PEG 100 g, sulfate 7.5 g, NaCl 2.691 g, KCl 1.015 g; each B:ascorbic acid 4.7 g and sodium ascorbate 5.9 g. Single carton NDC 65649-201-75.

Excluded mixtures

Plenvu, unverified other manufacturers/legacy NuLYTELY, sulfate-only preparations and PEG without electrolytes need separate label review; no regimen/interchangeability or current-stock assertion.

GoLYTELY powder 15–30°C sealed; reconstituted 2–8°C, do not freeze, discard after 48 hours. GaviLyte-N 25°C with 15–30°C excursions; refrigerate reconstituted and discard after 48 hours. MoviPrep 20–25°C with 15–30°C excursions; refrigerate upright after mixing, use within 24 hours. Do not transfer one product’s shelf life to another.